Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to reduce cardiovascular risk in patients with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors.
ASCVD refers to a build-up of plaque in the arteries which can reduce blood flow and lead to a range of conditions including peripheral artery disease, acute coronary syndrome (ACS) and stroke.
